Title:Recent Development of Hydrogen Sulfide Therapeutics in the Treatment of Cardiovascular Diseases
Volume: 21
Issue: 24
Author(s): Wen Peng, Weiwei Guo*Yueqing Zheng*
Affiliation:
- Academic Institute of Pharmaceutical Science China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing, 210009,China
- Academic Institute of Pharmaceutical Science China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing, 210009,China
Keywords:
Hydrogen sulfide (H2S), Gasotransmitter, Cardiovascular diseases (CVDs), H2S prodrug, Thrombosis, Astrocytes.
Abstract: Hydrogen sulfide (H2S), as one of the endogenous gasotransmitters, has shown great potential
in treating cardiovascular diseases (CVDs). H2S plays a protective role in CVDs by removing
reactive oxygen species (ROS), promoting vasodilation, inhibiting myocardial hypertrophy, preventing
thrombosis, and protecting mitochondria. However, there still exist some problems for H2S as
drugs such as challenging delivery, uncontrollable release rate, and other drug developability issues.
Addressing these problems, the prodrug strategy shows great potential. Therefore, a key issue on the
H2S-based therapeutics is developing appropriate H2S prodrugs. In this review, we mainly discussed
the mechanism of H2S against CVDs and reviewed the cardiovascular effects of current H2S prodrugs.
